ClinicalTrials.gg
CompletedNCT05784415CS22-03Updated Oct 28, 2026Results posted

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

An observational study in Leukemia, Leukemia, Lymphoblastic and Lymphoma, Large B-Cell, Diffuse, sponsored by AIDS Malignancy Consortium. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionPrecursor Cell Lymphoblastic Leukemia-LymphomaRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Why
  1. The study's listed conditions name Precursor Cell Lymphoblastic Leukemia-Lymphoma, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AIDS Malignancy Consortium · Observational

How we know

Updated Oct 28, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Enrollment
119th of 154
35 · median 110
Started
2021
with 35 others
Observational
155 of 1,545
28 open now
Registered
1,417th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 119th largest by enrollment of the 154 observational ones that give a count, is one of 36 that started in 2021, is one of 155 observational ones, and was the 1,417th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 30, 2023. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, who in turn will provide the AMC statistical center with de-identified data

Read the detailed description

Two landmark trials have led to the FDA approval of two different CD19 directed chimeric antigen receptor (CAR) T cell (CAR19) products in the United States for the treatment of relapsed or refractory (RR) large B-cell lymphoma after two or more lines of systemic therapy: tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta ®). In the ZUMA-1 registration trial for axicabtagene ciloleucel (axi-cel), 42% of the 101 treated patients achieved a complete response (CR), and with a median follow up of 15 months, the projected 1year progression free survival (PFS) was 70%. In a recent updated analysis, the CR rate was 58% with about 40% of patients having durable remissions at 2 years of follow up. Similar results were seen in the JULIET registrational trial for tisagenlecleucel (tisa-cel) with an overall response rate (ORR) of 52%, and a CR rate of 40% in the 93 patients evaluable for response; with a median follow up of 14 months, the estimated 12-months relapse-free survival was 65% (79% among patients with a CR). Tisagenlecleucel is also approved for the treatment of acute B-lineage lymphoblastic leukemia in patients up to the age of 25 years. Unfortunately, in both trials patients with known HIV infection were excluded. Therefore, no safety or efficacy data for treatment with CAR19 in PLWH exists, and access for PLWH in the US to this potentially curative treatment has been limited.

This has to be contrasted with the fact that malignancies, and specifically lymphomas, remain a major contributor to early mortality in PLWH. With a lifetime risk of cancer ranging between 24-40%, the leading cause of death in PLWH in economically developed countries is cancer, and the most common cancer in PLWH in the US remains Non-Hodgkin lymphoma (NHL). While early during the HIV epidemic, outcomes for PLWH and aggressive B-cell lymphomas were significantly worse compared to immunocompetent patients, this is no longer the case for the majority of PLWH, owing mainly to effective antiretroviral therapies leading to better tolerance of myelosuppressive chemotherapy and a consequent paradigm shift in aggressive therapies for HIV-associated lymphoma. It has been repeatedly demonstrated that PLWH have been able to safely tolerate aggressive high-dose chemotherapy, as well as autologous and even allogeneic hematopoietic cell transplant.

03

Conditions studied

  • Leukemia
  • Leukemia, Lymphoblastic
  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin
  • HIV Infections
  • HIV Associated Lymphoma
  • HIV Disease; Lymphoma

Keywords

  • B-cell lymphoma
  • acute lymphoblastic leukemia
  • CART cell therapy
  • CAR T-cell therapy
04

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma Reclassified

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

This study's enrollment of 35 is below the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.

Compared within Precursor Cell Lymphoblastic Leukemia-Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

People living with HIV treated with CD19-directed CAR T cell therapy for B-cell lymphoid malignancies

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of infection
  • Received CD19-directed CAR T cell therapy for acute lymphoblastic leukemia, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, or primary mediastinal B-cell lymphoma
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any CAR T cell therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
35 participants (actual)
Patient registry
No

Groups and cohorts

  • Observational

    Clinical information on participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021 will be captured

07

What researchers measure

Primary outcomes

  1. Rate of Toxicities Related to CAR19 Therapy

    Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria (for cytokine release syndrome). Maximum neurotoxicity will be reported. Grade 1 indicates a mild adverse event; Grade 2 indicates a moderate adverse event; Grade 3 indicates a severe adverse event; Grade 4 indicates life-threatening adverse event; and Grade 5 indicates death.

    Time frame: 12 months

Secondary outcomes

  1. Overall Response

    Overall response is defined as complete remission (CR) plus partial remission (PR) based on response assessment using the Lugano criteria.

    Time frame: 3 months and 6 months

  2. Complete Remission

    Complete remission is defined as complete disappearance of all disease based on response assessment using the Lugano criteria.

    Time frame: 3 months

  3. CD8 Count at 3 Months Post CAR-T

    CD8 count measured at 3 months post CAR-T will be reported

    Time frame: 3 months post CAR-T

  4. CD8 Count at 6 Months Post CAR-T

    CD8 count measured at 6 months post CAR-T will be reported.

    Time frame: 6 months post CAR-T

  5. CD8 Count at 9 Months Post-CAR T

    CD8 count measured at 9 months post CAR-T will be reported.

    Time frame: 9 months post-CAR T

  6. CD8 Count at 12 Months Post-CAR T

    CD8 count measured at 12 months post CAR-T will be reported.

    Time frame: 12 months post-CAR T

  7. HIV Viral Load at 3 Months Post-CAR T

    HIV viral load measured at 3 months post CAR-T will be reported.

    Time frame: 3 months post CAR-T

  8. HIV Viral Load at 6 Months Post-CAR T

    HIV viral load measured at 6 months post CAR-T will be reported.

    Time frame: 6 months post CAR-T

  9. HIV Viral Load at 9 Months Post-CAR T

    HIV viral load measured at 9 months post CAR-T will be reported.

    Time frame: 9 months post CAR-T

  10. HIV Viral Load at 12 Months Post-CAR T

    HIV viral load measured at 12 months post CAR-T will be reported.

    Time frame: 12 months post CAR-T

  11. Neutrophil Recovery

    Neutrophil recovery is defined as when ANC is greater than or equal to 500 per mm3 achieved and sustained for 3 lab values. The number of participants who experience neutrophil recovery will be reported.

    Time frame: 12 months after CAR-T

  12. Platelet Recovery

    Platelet recovery is defined as when platelet counts are greater than or equal to 20x10\^9 per L. The number of participants who experience platelet recovery will be reported.

    Time frame: 12 months after CAR-T

  13. Overall Survival

    Overall survival is defined as the elapsed time between HCT and the date of death.

    Time frame: Up to 2 years

  14. Progression-free Survival

    Progression-free survival is defined as elapsed time between HCT and disease progression or death from any cause. If a participant receives subsequent HCT, this participant will be censored as date of subsequent HCT.

    Time frame: Up to 2 years

08

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneObservational
Started35
Completed35
Not completed0

Outcome measures

PrimaryRate of Toxicities Related to CAR19 Therapy

Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria (for cytokine release syndrome). Maximum neurotoxicity will be reported. Grade 1 indicates a mild adverse event; Grade 2 indicates a moderate adverse event; Grade 3 indicates a severe adverse event; Grade 4 indicates life-threatening adverse event; and Grade 5 indicates death.

Time frame:
12 months
Reported as:
Count of participants · Participants
Rate of Toxicities Related to CAR19 Therapy
ParticipantsObservational
No neurotoxicity27
Grade 10
Grade 21
Grade 33
Grade 43
Grade 50
Not reported1
SecondaryOverall Response

Overall response is defined as complete remission (CR) plus partial remission (PR) based on response assessment using the Lugano criteria.

Time frame:
3 months and 6 months
Reported as:
Number · percentage of participants with CR/PR
Overall Response
percentage of participants with CR/PRObservational
At 3 months40 (24.4 to 57.8)
At 6 months40 (24.4 to 57.8)
SecondaryComplete Remission

Complete remission is defined as complete disappearance of all disease based on response assessment using the Lugano criteria.

Time frame:
3 months
Reported as:
Number · percentage of participants with CR
Complete Remission
percentage of participants with CRObservational
Complete Remission31.4 (17.4 to 49.4)
SecondaryCD8 Count at 3 Months Post CAR-T

CD8 count measured at 3 months post CAR-T will be reported

Time frame:
3 months post CAR-T
Reported as:
Median · cells/uL
CD8 Count at 3 Months Post CAR-T
cells/uLObservational
CD8 Count at 3 Months Post CAR-T314 (48 to 1704)
SecondaryCD8 Count at 6 Months Post CAR-T

CD8 count measured at 6 months post CAR-T will be reported.

Time frame:
6 months post CAR-T
Reported as:
Median · cells/uL
CD8 Count at 6 Months Post CAR-T
cells/uLObservational
CD8 Count at 6 Months Post CAR-T678 (113 to 1605)
SecondaryCD8 Count at 9 Months Post-CAR T

CD8 count measured at 9 months post CAR-T will be reported.

Time frame:
9 months post-CAR T
Reported as:
Median · cells/uL
CD8 Count at 9 Months Post-CAR T
cells/uLObservational
CD8 Count at 9 Months Post-CAR T1016 (70 to 1452)
SecondaryCD8 Count at 12 Months Post-CAR T

CD8 count measured at 12 months post CAR-T will be reported.

Time frame:
12 months post-CAR T
Reported as:
Median · cells/uL
CD8 Count at 12 Months Post-CAR T
cells/uLObservational
CD8 Count at 12 Months Post-CAR T1157 (65 to 1617)
SecondaryHIV Viral Load at 3 Months Post-CAR T

HIV viral load measured at 3 months post CAR-T will be reported.

Time frame:
3 months post CAR-T
Reported as:
Median · copies per mL
HIV Viral Load at 3 Months Post-CAR T
copies per mLObservational
HIV Viral Load at 3 Months Post-CAR T10 (0 to 59)
SecondaryHIV Viral Load at 6 Months Post-CAR T

HIV viral load measured at 6 months post CAR-T will be reported.

Time frame:
6 months post CAR-T
Reported as:
Median · copies per mL
HIV Viral Load at 6 Months Post-CAR T
copies per mLObservational
HIV Viral Load at 6 Months Post-CAR T26.5 (0 to 53)
SecondaryHIV Viral Load at 9 Months Post-CAR T

HIV viral load measured at 9 months post CAR-T will be reported.

Time frame:
9 months post CAR-T
Reported as:
Median · copies per mL
HIV Viral Load at 9 Months Post-CAR T
copies per mLObservational
HIV Viral Load at 9 Months Post-CAR T60 (53 to 582000)
SecondaryHIV Viral Load at 12 Months Post-CAR T

HIV viral load measured at 12 months post CAR-T will be reported.

Time frame:
12 months post CAR-T
Reported as:
Median · copies per mL
HIV Viral Load at 12 Months Post-CAR T
copies per mLObservational
HIV Viral Load at 12 Months Post-CAR T10 (0 to 178000)
SecondaryNeutrophil Recovery

Neutrophil recovery is defined as when ANC is greater than or equal to 500 per mm3 achieved and sustained for 3 lab values. The number of participants who experience neutrophil recovery will be reported.

Time frame:
12 months after CAR-T
Reported as:
Count of participants · Participants
Neutrophil Recovery
ParticipantsObservational
Neutrophil Recovery28
SecondaryPlatelet Recovery

Platelet recovery is defined as when platelet counts are greater than or equal to 20x10\^9 per L. The number of participants who experience platelet recovery will be reported.

Time frame:
12 months after CAR-T
Reported as:
Count of participants · Participants
Platelet Recovery
ParticipantsObservational
Platelet Recovery4
SecondaryOverall Survival

Overall survival is defined as the elapsed time between HCT and the date of death.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Overall Survival
percentage of participantsObservational
Overall survival at 100 days74.3 (58.7 to 87.2)
Overall survival at 6 months54.3 (37.8 to 70.3)
Overall survival at 1 year51.1 (34.7 to 67.4)
Overall survival at 2 years38.9 (20.8 to 58.8)
SecondaryProgression-free Survival

Progression-free survival is defined as elapsed time between HCT and disease progression or death from any cause. If a participant receives subsequent HCT, this participant will be censored as date of subsequent HCT.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Progression-free Survival
percentage of participantsObservational
Progression-free survival at 100 days50 (31.9 to 68.1)
Progression-free survival at 6 months42.9 (25.4 to 61.3)
Progression-free survival at 1 year35.7 (19.3 to 54)
Progression-free survival at 2 years28.6 (12 to 48.8)

Adverse events

Collected over Up to 2 years after CAR-T for mortality and 12 months after CAR-T for cytokine release syndrome (CRS) and neurotoxicity.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Observational19/35 (54.3%)0/35 (0%)24/35 (68.6%)
Most frequent other events
Most frequent other events
EventObservational
Cytokine release syndromBlood and lymphatic system disorders24/35
NeurotoxicityNervous system disorders8/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Observational
Median56 (28.6 to 69.4)
Age, Customized
Age, Customized(Participants)Observational
20-29 years2
30-39 years7
40-49 years6
50-59 years9
60-69 years11
Sex: Female, Male
Sex: Female, Male(Participants)Observational
Female4
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Observational
Hispanic or Latino6
Not Hispanic or Latino26
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Observational
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American9
White20
More than one race0
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(participants)Observational
United States35
Disease type
Disease type(Participants)Observational
DLBCL32
Follicular, predominantly small cleaved cell1
Mantle cell Lymphoma1
Follicular, predominantly large cell, grade IIIB1
Karnofsky/Lansky performance score prior to CAR-T
Karnofsky/Lansky performance score prior to CAR-T(Participants)Observational
90-10017
809
<809

15 further baseline measures are reported on the registry.

09

Study locations

1 site
  • Pennsylvania Hospital
    Philadelphia, Pennsylvania 19106, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2024, 41 months.

Results were first posted in Oct 2026, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
May 22, 2021
Primary completionActual
Nov 14, 2024
CompletionActual
Nov 14, 2024
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Enrollment
30→35
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRate of toxicities relatedToxicities Related to CAR19 therapyTherapyTime frame: 12 months
Oct 28, 2026
Documents
Secondary outcomes
2 edited, 12 added, 3 removed
What changed in the outcomes
  • EditedOverall responseResponseTime frame: 3 months and 6 months
  • EditedComplete remissionRemissionTime frame: 3 months and 6 months → 3 months
  • AddedCD8 Count at 3 Months Post CAR-TTime frame: 3 months post CAR-T
  • AddedCD8 Count at 6 Months Post CAR-TTime frame: 6 months post CAR-T
  • AddedCD8 Count at 9 Months Post-CAR TTime frame: 9 months post-CAR T
  • AddedCD8 Count at 12 Months Post-CAR TTime frame: 12 months post-CAR T
  • AddedHIV Viral Load at 3 Months Post-CAR TTime frame: 3 months post CAR-T
  • AddedHIV Viral Load at 6 Months Post-CAR TTime frame: 6 months post CAR-T
  • AddedHIV Viral Load at 9 Months Post-CAR TTime frame: 9 months post CAR-T
  • AddedHIV Viral Load at 12 Months Post-CAR TTime frame: 12 months post CAR-T
  • AddedNeutrophil RecoveryTime frame: 12 months after CAR-T
  • AddedPlatelet RecoveryTime frame: 12 months after CAR-T
  • AddedOverall SurvivalTime frame: Up to 2 years
  • AddedProgression-free SurvivalTime frame: Up to 2 years
  • RemovedChange in CD4 countTime frame: Day 0, 3 months, 6 months, and 12 months post CAR19 therapy
  • RemovedAbsolute lymphocyte countTime frame: Day 0, 3 months, 6 months, and 12 months post CAR19 therapy
  • RemovedHIV viral loadTime frame: Day 0, 3 months, 6 months, and 12 months post CAR19 therapy
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Enrollment 30→35
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRate of toxicities relatedToxicities Related to CAR19 therapyTherapyTime frame: 12 months
    Secondary outcomes 2 edited, 12 added, 3 removed
    What changed in the outcomes
    • EditedOverall responseResponseTime frame: 3 months and 6 months
    • EditedComplete remissionRemissionTime frame: 3 months and 6 months → 3 months
    • AddedCD8 Count at 3 Months Post CAR-TTime frame: 3 months post CAR-T
    • AddedCD8 Count at 6 Months Post CAR-TTime frame: 6 months post CAR-T
    • AddedCD8 Count at 9 Months Post-CAR TTime frame: 9 months post-CAR T
    • AddedCD8 Count at 12 Months Post-CAR TTime frame: 12 months post-CAR T
    • AddedHIV Viral Load at 3 Months Post-CAR TTime frame: 3 months post CAR-T
    • AddedHIV Viral Load at 6 Months Post-CAR TTime frame: 6 months post CAR-T
    • AddedHIV Viral Load at 9 Months Post-CAR TTime frame: 9 months post CAR-T
    • AddedHIV Viral Load at 12 Months Post-CAR TTime frame: 12 months post CAR-T
    • AddedNeutrophil RecoveryTime frame: 12 months after CAR-T
    • AddedPlatelet RecoveryTime frame: 12 months after CAR-T
    • AddedOverall SurvivalTime frame: Up to 2 years
    • AddedProgression-free SurvivalTime frame: Up to 2 years
    • RemovedChange in CD4 countTime frame: Day 0, 3 months, 6 months, and 12 months post CAR19 therapy
    • RemovedAbsolute lymphocyte countTime frame: Day 0, 3 months, 6 months, and 12 months post CAR19 therapy
    • RemovedHIV viral loadTime frame: Day 0, 3 months, 6 months, and 12 months post CAR19 therapy
    + 5 other changes: index terms, verification date, description, contact details and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05784415
Lead sponsor
AIDS Malignancy Consortium
Collaborators
Center for International Blood and Marrow Transplant Research
Responsible party
Sponsor
First posted
Mar 24, 2023
Start date
May 22, 2021
Primary completion
Nov 14, 2024
Completion
Nov 14, 2024
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Stefan Barta, MD
principal investigator · AIDS Malignancy Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion